Status:

COMPLETED

A Study of Ixekizumab in Healthy Participants

Lead Sponsor:

Eli Lilly and Company

Conditions:

Healthy

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to compare three different formulations of ixekizumab. One formulation (Reference) has been approved by the Food and Drug Administration (FDA) and two formulations (Test 1...

Eligibility Criteria

Inclusion

  • Healthy male participant or female participant who agree to not become pregnant
  • Are male participant or female participants with chronic stable medical problems, that in the investigator's opinion will not place the subject at increased risk by participating in the study

Exclusion

  • Have a significant history of, or current, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or hematologic disorders that in the opinion of the investigator poses an unacceptable risk to the participant if participating in the study
  • Are allergic or hypersensitive to the study medicine
  • Had a vaccination with a live vaccine within 12 months prior to the first check-in or intend to get a vaccine for tuberculosis within 12 months of completing treatment on this study
  • Have any type of hepatitis, human immunodeficiency virus (HIV) infection, or other serious infection
  • Show evidence of active or latent tuberculosis (TB)
  • Presence of significant neuropsychiatric disorder or a recent history of depression
  • Have had any active or recent infection within 4 weeks of Day 1 that, in the opinion of the investigator would pose an unacceptable risk to the participant, if participating in the study

Key Trial Info

Start Date :

January 29 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 7 2019

Estimated Enrollment :

99 Patients enrolled

Trial Details

Trial ID

NCT03848416

Start Date

January 29 2019

End Date

June 7 2019

Last Update

June 24 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Covance Clinical Research Inc

Daytona Beach, Florida, United States, 32117